[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-bypass-grafting\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-bypass-grafting":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,39,68,113,138,161,198,224,252,276,301,328,353,370,395,419,453,475],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100637997","cardiac-rehab-referral-nudges-100637997",false,"NCT07607522","Cardiac Rehab Referral Nudges","Inclusion Criteria:\n\n* Age of at least 18 years\n* History of Coronary Artery Bypass Grafting (CABG), Percutaneous Coronary Intervention (PCI), or valve repair\u002Freplacement in the past year\n\nExclusion Criteria:\n\n* Hospice\n* Active home health","ALL","18 Years",{"count":18,"type":19},7000,"ESTIMATED","OBSERVATIONAL","Investigators will evaluate the effectiveness of two different EHR-embedded nudges to improve referral to cardiac rehabilitation.",[23,24,25],"Percutaneous Coronary Intervention","Valve Repair\u002FReplacement","Coronary Artery Bypass Grafting","NOT_YET_RECRUITING","2026-05-19",{"date":29,"type":30},"2026-05-26","ACTUAL",{"date":32,"type":19},"2026-06-15",{"date":34,"type":19},"2026-12-15",{"name":36,"class":37},"NYU Langone Health","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":48,"conditions":49,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":38},"100640251","trajectory-based-phenotyping-after-coronary-artery-bypass-surgery-100640251","NCT07598682","Trajectory-Based Phenotyping After Coronary Artery Bypass Surgery","Early Postoperative Trajectory-Based Phenotyping Improves Risk Stratification Beyond EuroSCORE in Patients Undergoing Coronary Artery Bypass Grafting","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients who underwent elective on-pump coronary artery bypass grafting\n* Patients operated between January 1, 2022 and December 31, 2025\n* Patients with available perioperative clinical and laboratory data required for analysis\n\nExclusion Criteria:\n\n* Patients undergoing emergency surgery\n* Patients undergoing concomitant valve surgery\n* Patients with missing or inconsistent key clinical or laboratory data",{"count":47,"type":19},1000,"Coronary artery bypass grafting is a commonly performed heart surgery, but patients may have different risks for postoperative complications even when their preoperative risk scores are similar. EuroSCORE II is widely used to estimate surgical risk before cardiac surgery, but it may not fully reflect how the body responds during the early postoperative period.\n\nThis retrospective observational study will evaluate adult patients who underwent elective coronary artery bypass grafting with cardiopulmonary bypass between January 1, 2022 and December 31, 2025. The study will use existing hospital records and laboratory data. No additional treatment, test, or intervention will be given to patients as part of this study.\n\nThe main aim is to examine whether early postoperative changes in inflammatory and renal laboratory markers can identify different patient subgroups, called phenotypes. These markers include neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, triglyceride-glucose index, and serum creatinine. The study will evaluate whether these phenotype groups are associated with postoperative acute kidney injury and prolonged intensive care unit stay.\n\nThe study will also assess whether this early postoperative phenotype-based classification provides additional risk information beyond EuroSCORE II.",[25,50,51,52],"Postoperative Acute Kidney Injury","Postoperative Complications","Risk Stratification",[54,55,56,57],"Coronary artery bypass grafting","Postoperative phenotyping","EuroSCORE II","Risk stratification","2026-05-13",{"date":60,"type":30},"2026-05-20",{"date":62,"type":19},"2026-05-07",{"date":64,"type":19},"2026-07-01",{"name":66,"class":67},"Bursa Sevket Yilmaz Training and Research Hospital","OTHER_GOV",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":97,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":38},"100592604","dietary-supplements-in-patients-with-coronary-artery-bypass-grafting-for-improving-the-quality-of-healthcare-delivery-100592604","NCT06995586","Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","The Synergistic Action of Vitamins and Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","Inclusion Criteria:\n\n* The subjects will be people 40-80 years old, with coronary artery disease, and mental clarity who will undergo Coronary Aortic Bypass (CABG) in our clinic (Public Cardiothoracic Surgery clinic in Nicosia General Hospital) and will be randomized into 2 groups (intervention group and control group).\n* Signed consent form\n* Ability to adhere to the protocol\n\nExclusion Criteria:\n\n* Any psychiatric, neurological or motor disorder.\n* Hypersensitivity to the components of the supplement.\n* Combined Cardiac Surgery other than CABG and valve or aortic\n* Concurrent participation in other clinical trials.\n* Previous use of any probiotics, prebiotics, adsorbent dietary supplements, Vitamin C and\u002For Omega 3 fatty acids.","40 Years","80 Years",{"count":78,"type":19},108,"INTERVENTIONAL",[81],"NA","Cardiovascular disease (CVD) remains the leading cause of death worldwide. Prevention of CAD by targeting modifiable factors remains a key public health priority. L-Ascorbic Acid (Vitamin C - Vit. C) and Omega 3 fatty acids, Eicosapentaenoic \u002F Docosahexaenoic Acid (EPO\u002FDHA), powerful but also necessary antioxidants for the human body, after observational studies as well as randomized studies seem to have a beneficial effect in the direction of the prevention of CVD with pleiotropic mechanisms. Lignin, a polymer of plant origin that is considered a dietary fiber, has a developed porous structure and can retain exogenous and endogenous toxins, and pathogenic microorganisms. Lactulose considered a prebiotic provides a selective substrate for the metabolism of saccharolytic bacteria with bifidogenic activity and multiple benefits to the host's gut health. Coronary artery bypass grafting (CABG) is an established surgical intervention and treatment of symptoms of myocardial ischemia that improves patient survival Optimal Medical Therapy (OMT) after coronary arterial bypass grafting (CABG) as described in current clinical practice could be made even better by the addition of these beneficial food supplements.\n\nA randomized controlled trial is proposed in an intervention group of 54 post-CABG patients who will be given daily orally in addition to the usual medication, 1000 mg Vitamin C, 840 mg EPO\u002FDHA, 2130 mg Lignin \\& 720 mg Lactulose and a control group of 54 patients (Control Group) in which only usual medication will be administered. The intervention will take place from the 15th postoperative day when CAGB patients are discharged and lasts for 2.5 months (10 weeks) postoperatively. The data will be collected on the 15th, 80-90th postop day in 6 months and 12 months postop and then the statistical analysis of the data will be performed. Considering the number of CABG surgeries performed electively in our clinic, this study is expected to be completed in approximately 2-3 years from the day of initiation.\n\nThe expected knowledge through the expected results such as these will emerge from this study is the potentially beneficial effect of our food supplements administration (intervention), i.e. Vitamin C, EPO\u002FDHA, Lignin \\& Lactulose, on the postoperative course of our patients. Some degree of improvement in the well-being and clinical picture of our patients postoperatively is expected, which will be thoroughly investigated in each phase of the study.",[84,85,86,87,88,89,90,91,92,93,94,95,25,96],"Cardio-pulmonary Bypass","Cardiovascular Diseases","Omega-3 Polyunsaturated Fatty Acids","Omega-3 Supplementation","Vitamin C","Supplements","Postoperative Depression","Antioxidants","Lactulose","Postoperative","Optimal Medical Therapy","CABG","Prebiotics",[84,85,98,88,91,92,99,89,100,94,95,25,101,102,103,104],"Omega-3 polyunsaturated fatty acids","Omega-3 supplementation","postoperative","postoperative depression","Lignin","adsorbent","prebiotics","2026-05-09",{"date":58,"type":30},{"date":108,"type":19},"2026-09-01",{"date":110,"type":19},"2028-12-01",{"name":112,"class":37},"Nicosia General Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":120,"targetDuration":4,"studyType":79,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":38},"100597378","total-arterial-vs-mixed-grafting-in-left-coronary-cabg-100597378","NCT07057713","Total Arterial vs. Mixed Grafting in Left Coronary CABG","A Prospective, Randomized, Double-Blind Controlled Trial Comparing Total Arterial Grafting Versus Conventional Mixed Grafting in the Left Coronary Artery System During Coronary Artery Bypass Grafting (CABG)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Diagnosed with multivessel coronary artery disease\n3. Indicated for elective coronary artery bypass grafting (CABG) involving ≥3 coronary vessels\n4. Right coronary artery stenosis \\>75%\n5. Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n1. Scheduled for concurrent cardiac procedures (e.g., valve surgery, congenital heart disease repair, aortic dissection surgery, atrial fibrillation ablation)\n2. Severe stenosis of left or right subclavian artery\n3. Unsuitable saphenous veins (e.g., bilateral varicosities)\n4. Unsuitable radial artery as assessed preoperatively\n5. History of intracranial hemorrhage or ischemic stroke within the past 14 days\n6. Severe hepatic or renal insufficiency\n7. Acute myocardial infarction within 72 hours prior to surgery\n8. History of prior CABG or other cardiac surgery",{"count":121,"type":19},400,[81],"This is a prospective, randomized, double-blind controlled trial comparing the clinical efficacy of total arterial grafting (internal thoracic artery and radial artery) versus conventional mixed grafting (internal thoracic artery and great saphenous vein) in the left coronary artery system during coronary artery bypass grafting (CABG). A total of 400 patients undergoing elective CABG at the Second Hospital of Jilin University will be enrolled and randomized into two groups. The primary endpoint is graft patency at 12 months postoperatively, evaluated by coronary angiography or CT angiography. Secondary outcomes include perioperative complications, major adverse cardiovascular events (MACE), and long-term clinical prognosis. The study aims to provide evidence-based guidance on optimal graft selection in CABG.",[125,25,126,127,128],"Coronary Artery Disease","Arterial Graft","Graft Patency","Major Adverse Cardiovascular Events","2026-04-21",{"date":131,"type":30},"2026-04-23",{"date":133,"type":19},"2026-08-01",{"date":135,"type":19},"2027-12-30",{"name":137,"class":37},"Second Hospital of Jilin University",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":146,"targetDuration":4,"studyType":79,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":38},"100591512","ticagrelor-based-dual-antiplatelet-therapy-duration-in-cabg-100591512","NCT06981390","Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG","Ticagrelor-Based Dual Antiplatelet Therapy in Coronary Artery Bypass Grafting: A Randomized Clinical Trial on Graft Patency","Inclusion Criteria:\n\n1. Patients 18-80 of age.\n2. Patients undergo planned CABG for the first time with ≥1 SVGs\n3. Patients with written informed consent.\n\nExclusion Criteria:\n\n1. Patients undergoing concomitant valve surgery (excluding aortic bioprosthesis), aortic surgery, or rhythm surgery during the same session.\n2. Patients undergoing emergency CABG.\n3. Patients with single-vessel coronary artery disease.\n4. Patients with cardiogenic shock or hemodynamic instability.\n5. Patients with sick sinus syndrome, second- or third-degree atrioventricular block.\n6. Patients with contraindications for coronary computed tomography angiography (CCTA) or coronary angiography, including contrast media allergy.\n7. Patients requiring antiplatelet therapy other than aspirin or ticagrelor (e.g., clopidogrel, prasugrel) and unable to discontinue such medication after CABG, based on physician or investigator judgment.\n8. Patients on oral anticoagulants before CABG who must continue anticoagulation therapy postoperatively.\n9. Patients with contraindications for ticagrelor or aspirin, including:\n\n   9.1Bleeding diathesis within the past 3 months. 9.2Severe gastrointestinal bleeding within the past year. 9.3Peptic ulcer (even without bleeding) within the past 3 years. 9.4History of intracranial hemorrhage, aspirin allergy, or severe aspirin-induced gastrointestinal reaction.\n10. Patients with a drug-eluting stent (DES) in a coronary or cerebral artery within 6 months before CABG, or a bare-metal stent (BMS) within 1 month before CABG.\n11. Patients with thrombocytopenia (\\\u003C100 x 10⁹\u002FL) before CABG.\n12. Patients with severe renal dysfunction requiring dialysis or active liver disease, including unexplained persistent transaminase elevation or transaminase levels \\>3× the upper normal limit.\n13. Patients using strong CYP3A4 inhibitors.\n14. Patients requiring methotrexate and ibuprofen therapy.\n15. Patients with active malignant tumors with an increased risk of bleeding, as determined by the investigator.\n16. Pregnant or breastfeeding women, and those who have given birth within the past 90 days.\n17. Premenopausal women not using adequate contraception. Adequate contraception requires at least two reliable methods, including one barrier method.",true,{"count":147,"type":19},300,[81],"This randomized controlled trial aims to evaluate the impact of different durations of Ticagrelor-based dual antiplatelet therapy (DAPT) on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting (CABG). A total of 300 patients will be randomly assigned to receive Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, 6 months, or 12 months, followed by aspirin monotherapy.The primary outcome is 1-year graft patency, assessed via coronary CT angiography. Secondary outcomes include bleeding events (BARC classification), major adverse cardiovascular and cerebrovascular events (MACCE), and all-cause mortality. The study aims to determine the optimal DAPT duration to balance graft patency benefits and bleeding risks, ultimately guiding postoperative antiplatelet strategies for CABG patients.",[125,25,151,152],"Saphenous Vein","Dual Antiplatelet Therapy",{"date":154,"type":30},"2026-04-24",{"date":156,"type":19},"2026-05-01",{"date":158,"type":19},"2027-03-20",{"name":160,"class":37},"Kexiang Liu, MD",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":79,"phases":171,"briefSummary":172,"conditions":173,"keywords":179,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":194,"leadSponsor":196,"locationsCount":38},"100633038","llm-based-intelligent-health-management-assistant-in-life-cycle-health-management-of-cardiac-surgery-patients-100633038","NCT07521488","LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients","Application of Large Language Model-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Patients After Cardiac Surgery: A Prospective Randomized Controlled Study","cFT-LLM","Inclusion Criteria:\n\n1. Aged 18 years or older, any sex\n2. Underwent cardiac surgery at the Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, including but not limited to: coronary artery bypass grafting (CABG), heart valve replacement or repair (aortic valve, mitral valve, or tricuspid valve surgery), great vessel surgery (aortic dissection or aortic aneurysm repair), congenital heart disease correction, or cardiac assist device implantation\n3. Clinically stable after surgery and eligible for hospital discharge\n4. Has access to a smartphone and is capable of independently operating a mobile application, or has a family member available to assist with operation\n5. Voluntarily participates in the study, understands and signs the informed consent form, and is able to comply with the study protocol requirements\n\nExclusion Criteria:\n\n1. Postoperative intensive care unit (ICU) stay exceeding 30 days, or presence of severe uncontrolled postoperative complications such as persistent infection or multi-organ failure\n2. Life expectancy less than 12 months due to advanced malignancy or end-stage organ failure\n3. Severe cognitive impairment, psychiatric disorder, or inability to understand and use a mobile application without available caregiver assistance\n4. Heart transplant recipient\n5. Currently participating in another interventional clinical study\n6. Anticipated inability to complete 12-month follow-up",{"count":170,"type":19},500,[81],"This is a single-center, prospective, randomized, open-label, parallel-controlled clinical study to evaluate the effectiveness of a large language model (LLM)-based intelligent health management assistant in the life-cycle health management of patients after cardiac surgery. A total of 500 adult patients who undergo cardiac surgery (including coronary artery bypass grafting, heart valve surgery, great vessel surgery, congenital heart disease correction, and other cardiac procedures) at Beijing Anzhen Hospital will be randomly assigned in a 1:1 ratio to an intervention group or a control group, stratified by age (\\\u003C65 vs ≥65 years) and surgery type. The intervention group will use the LLM-based mobile health management application in addition to standard postoperative care, while the control group will receive standard postoperative care alone. The application integrates multimodal clinical data into a personalized health profile and provides surgery-type-specific postoperative management recommendations, medication adherence reminders, complication early warning, and cardiac rehabilitation guidance. The primary outcome is the composite endpoint of major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause death, non-fatal myocardial infarction, non-fatal stroke, or unplanned cardiovascular reoperation\u002Freintervention, within 12 months after randomization. Secondary outcomes include health-related quality of life (EQ-5D-5L), cardiovascular rehospitalization rate, medication adherence (MMAS-8), postoperative complication rate, and cardiac rehabilitation achievement rate. Follow-up visits are scheduled at 1, 3, 6, 9, and 12 months post-randomization.",[25,174,175,176,177,178],"Heart Valve Disease","Aortic Aneurysm","Aortic Dissection","Congenital Heart Disease","Cardiac Surgical Procedures",[180,181,182,183,184,185,186,187,188,189],"Large Language Model","Artificial Intelligence","Cardiac Surgery","Postoperative Health Management","Digital Health","Medication Adherence","Cardiac Rehabilitation","MACCE","Mobile Health Application","Personalized Health Management","2026-04-08",{"date":192,"type":30},"2026-04-13",{"date":156,"type":19},{"date":195,"type":19},"2027-12-31",{"name":197,"class":37},"Beijing Anzhen Hospital",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":206,"minAge":16,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":79,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":223},"100372032","comparison-of-the-outcomes-of-single-vs-multiple-arterial-grafts-in-women-100372032","NCT04124120","Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women","Randomized Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women (ROMA:Women) Trial","ROMA:Women","Inclusion Criteria:\n\n1. Women patients ≥18 years old.\n2. Isolated coronary artery bypass grafting.\n3. Primary (first time) cardiac surgery procedure.\n4. Significant disease of the left main coronary artery or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.\n\nExclusion Criteria:\n\n* Male gender\n* Single graft\n* Emergency operation\n* Myocardial infarction within 72 hours of surgery\n* Left ventricular ejection fraction \\\u003C 35%\n* Any concomitant cardiac or non-cardiac procedure\n* Previous cardiac surgery\n* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduces life expectancy to less than 5 years.\n* Inability to use the saphenous vein or to use both radial and right internal thoracic arteries\n* Anticipated need for coronary thrombo-endarterectomy\n* Planned hybrid revascularization","FEMALE",{"count":208,"type":19},2300,[81],"The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grafting (SAG).\n\nThe specific aims of ROMA:Women are:\n\nAim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grafting (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,300 women randomized 1:1 to MAG or SAG. Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time.\n\nHypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events.\n\nHypothesis 1.1. The improvement with MAG will be consistent across key subgroups.\n\nAim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated.\n\nHypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG.\n\nHypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG.\n\nHypothesis 2.2. The improvement with MAG will be consistent across key subgroups.",[212,125,25],"Heart Diseases","RECRUITING","2026-03-31",{"date":216,"type":30},"2026-04-01",{"date":218,"type":30},"2023-04-17",{"date":220,"type":19},"2030-03",{"name":222,"class":37},"Weill Medical College of Cornell University",146,{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":79,"phases":234,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100601917","phase-3-desflurane-vs-propofol-for-cardiac-anesthesia-100601917","NCT07116733","Desflurane vs. Propofol for Cardiac Anesthesia","Desflurane vs. Propofol for Cardiac Anesthesia: Impact on Developing Major Cardiac Events in Patients Undergoing CABG Procedure","DECIDE-CABG","Inclusion Criteria:\n\n1. Patients scheduled for elective coronary artery bypass grafting (CABG)\n2. Age ≥ 18 years old;\n3. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Emergency or urgent operation\n2. Concomitant valve or aortic surgery\n3. History of myocardial infarction in recent 30 days\n4. Current use of myocardial preconditioning-affecting medications, such as sulfonylurea (glibenclamide), allopurinol, theophylline, nicorandil(last dose \\\u003C 8 hrs), etc\n5. Participated in other randomized controlled clinical trials in recent 3 months\n6. General anesthesia in recent 30 days\n7. History of kidney and liver transplantation, or severe liver and kidney dysfunction (EGFR ≤ 20 mlgmin\u002F1.73 m2, conventional dialysis or patients who have started dialysis; Child Pugh grade C\u002Fcirrhosis)\n8. History of open heart surgery;\n9. Hemodynamic instability or severe heart failure (SBP\\\u003C90 mmHg or preoperative need of high-dose vasoactive drug support, placement of aortic balloon pump (IABP), ECMO or ventricular assist device, left ventricular ejection fraction\\\u003C30%)\n10. Adverse drug reactions to trial medications\n11. History of malignant hyperthermia\n12. Pregnancy or lactation",{"count":233,"type":19},3560,[235],"PHASE3","To investigate whether the inhaled anesthetic desflurane, compared with propofol, exerts cardioprotective effects and reduces the incidence of severe postoperative major cardiac events in patients undergoing coronary artery bypass graft (CABG) surgery.",[182,25],[239,240,182,241,25],"Desflurane","Propofol","Major Cardiac Event","2025-11-19",{"date":244,"type":30},"2025-11-25",{"date":246,"type":30},"2025-10-20",{"date":248,"type":19},"2029-12-31",{"name":250,"class":37},"Xijing Hospital",14,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":259,"targetDuration":261,"studyType":20,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":38},"100606212","safety-and-effectiveness-of-no-touch-technique-for-ascending-aorta-in-mics-cabg-100606212","NCT07172620","Safety and Effectiveness of No-touch Technique for Ascending Aorta in MICS-CABG","Safety and Effectiveness of No-touch Technique for Ascending Aorta in Minimally Invasive Cardiac Surgery Coronary Artery Bypass Grafting(MICS-CABG)","Inclusion Criteria:\n\n* Patients with angina pectoris who experience functional limitations in daily life and work despite conservative medical treatment and who require coronary artery bypass grafting surgery, as confirmed by coronary angiography, are eligible for enrollment.\n* Patients with calcification of the ascending aorta, as confirmed by CT, who are not suitable for sidewall clamping are also eligible for enrollment.\n\nExclusion Criteria:\n\n* The patient presents with an old, large myocardial infarction with no surviving myocardium, as evidenced by both isotope and echocardiographic imaging. This is a group of patients who are prone to complications, including significant cardiac enlargement, a cardiothoracic ratio greater than 0.75, an ejection fraction (EF) less than 30%, a left ventricular diameter (LVDd) greater than 70mm, the presence of a left ventricular ventricular wall tumor, or severe arrhythmia. Intraoperative hemodynamic instability;\n* Valve surgery or other intracardiac surgery at the same time;\n* Patients expected to undergo extracorporeal circulation surgery;\n* Poor myocardial infarction conditions, extensive lesions, distal or full diffuse stenosis, or lumen diameter less than or severe calcification that cannot be anastomosed.\n* Previous open heart surgery.\n* Patients with preoperative hemodynamic instability requiring emergency surgery.\n* Other conditions include terminal malignant tumors, uncontrollable infections, bleeding, persistent progressive degenerative systemic diseases, severe brain injuries, and multiple organ failure. Additionally, other significant organ function serious impairments, such as severe liver function impairment, severe heart failure, or cardiogenic shock, may also be considered contraindications. Inability to tolerate surgery may also be considered a contraindication.\n* The participant declines to take part in this study.",{"count":260,"type":19},260,"5 Years","The goal of this single-center prospective cohort study is to compare perioperative safety metrics and follow-up survival analyses in patients receiving Minimally Invasive Cardiac Surgery Coronary Artery Bypass Grafting(MICS-CABG) and Off-Pump Coronary Artery Bypass(OPCAB). The main question it aims to answer is:\n\nIs the bridge vessel patency rate of patients in the MICS-Notouch group noninferior to that of a saphenous vein bridge with conventional open-chest bypass?\n\nParticipants will be divided into two groups:\n\nExposure group (MICS-Notouch group): non-extracorporeal circulation multiple coronary artery bypass grafting surgery performed under direct visualization of a small incision in the left chest, including the application of LIMA (left internal mammary artery) + SVG (saphenous vein) multiple bypass grafting.\n\nControl group (OPCAB group): conventional median chest opening, non-extracorporeal circulation multi-branch coronary artery bypass graft surgery.",[25,264,265,266],"Off-pump Coronary Artery Bypass","Minimally Invasive Cardiac Surgery","Coronary Arterial Disease (CAD)","2025-09-11",{"date":269,"type":30},"2025-09-15",{"date":271,"type":30},"2025-06-01",{"date":273,"type":19},"2030-12-31",{"name":275,"class":37},"Peking University Third Hospital",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":79,"phases":286,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":38},"100577470","phase-4-the-effect-of-colchicine-on-the-occurrence-of-atrial-fibrillation-after-cardiac-surgery-100577470","NCT06798714","The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery","The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery (CAFE)","CAFE","Inclusion Criteria:\n\n1. Elective coronary artery bypass grafting on pump;\n2. signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Reduced left ventricular ejection fraction (≤35%);\n2. Valvular heart disease requiring surgical correction;\n3. Liver failure with an increase in liver transaminases ≥1.5 times;\n4. Renal failure (GFR\\\u003C35 mL\u002Fmin\u002F1.73 m2 calculated with CKD-EPI);\n5. Permanent, persistent or paroxysmal atrial fibrillation;\n6. Previously implanted pacemaker;\n7. Hypersensitivity to colchicine;\n8. Neutropenia;\n9. History of alcoholism;\n10. Refusal to sign informed consent",{"count":285,"type":19},140,[287],"PHASE4","Development of a new comprehensive method for perioperative prevention of atrial fibrillation paroxysms in cardiac surgery patients at the hospital stage.\n\nIt is planned to recruit 70 patients who will undergo pericardial fenestration during the operation using the original technique during coronary artery bypass grafting (Patent No. 2647626 C1 Russian Federation), and will be prescribed colchicine (the drug \"Colchicum-dispert\") in the perioperative period in order to prevent the development of paroxysms of atrial fibrillation in the postoperative period, and 70 cardiac surgery patients operated on using the standard technique (without performing the pericardial fenestration procedure intraoperatively), receiving non-steroidal anti-inflammatory drugs in the postoperative period.",[125,290,25,291],"Atrial Fibrillation","Colchicine","2025-09-02",{"date":294,"type":30},"2025-09-09",{"date":296,"type":30},"2025-01-20",{"date":298,"type":19},"2026-02-20",{"name":300,"class":37},"Tomsk Cardiology Research Institute",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":15,"minAge":309,"maxAge":76,"enrollmentInfo":310,"targetDuration":4,"studyType":79,"phases":312,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":38},"100541218","early-phase-1-thiamine-intervention-and-coronary-artery-bypass-grafting-100541218","NCT06326996","Thiamine Intervention and Coronary Artery Bypass Grafting","Thiamine Intervention and Cognition in Older Adults Undergoing Coronary Artery Bypass Grafting - A Randomized Clinical Trial.","B1&CABG","Inclusion Criteria:\n\n* Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)\n* Thiamine deficiency before CABG\n* European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) \\>1.5%\n* Off-pump surgery\n\nExclusion Criteria:\n\n* Dementia at baseline \\[Montreal Cognitive Assessment (MoCA) \\\u003C21 within 5 days before CABG\\]\n* Current in-take of thiamine\n* Known thiamine allergy\n* Uncontrolled blood glucose levels\n* Unable to give consent due to illness\n* History of hyperlactatemia\n* Recent (within several years and\u002For up to the judgment of the PI\u002Fco-PIs) cerebral incidents (seizure or head trauma resulting in loss of consciousness and\u002For concussion)\n* Stroke\n* Diagnosed psychiatric diseases (clinical depression, schizophrenia, manic-depression)\n* Patients with history of alcohol or substance abuse\n* Acute or chronic infections (tuberculosis, hepatitis, or encephalopathy)\n* Diagnosed neuro-degenerative diseases (Alzheimer's or Parkinson's disease)\n* Chronic immunodeficiency (including HIV)\n* Congenital brain deficits will also be excluded","60 Years",{"count":311,"type":19},52,[313],"EARLY_PHASE1","The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.",[316,25],"Coronary Heart Disease",[318],"thiamine intervention","2025-07-30",{"date":321,"type":30},"2025-08-01",{"date":323,"type":30},"2024-10-10",{"date":325,"type":19},"2026-09-30",{"name":327,"class":37},"University of California, Los Angeles",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":15,"minAge":335,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":79,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":38},"100488464","phase-4-pregabalin-versus-dexmedetomidine-for-delirium-treatment-after-coronary-artery-bypass-grafting-100488464","NCT05640453","Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting","Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting: A Randomized Double-Blind Trial","Inclusion Criteria:\n\n* CABG patients ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III planned for fast track developed postoperative delirium (POD).\n\nExclusion Criteria:\n\n* Patients who had history of psychiatric diseases; inability to communicate;\n* previous history of POD; preoperative sick sinus syndrome, allergy\u002Fsensitivity to pregabalin or dexmedetomidine, severe bradycardia (heart rate \\\u003C50 beat per minute), second-degree or above atrioventricular block without pacemaker; severe hepatic or renal insufficiency.\n* Previous cardiac or thoracic surgery, known diagnosis of depression or other major psychiatric diseases, cognitive impairment or inability to cooperate with the study, renal insufficiency, and history of substance abuse.","65 Years",{"count":337,"type":19},70,[287],"The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.",[341,342,25,343],"Pregabalin","Delirium Treatment","Dexmedetomidine","2025-06-23",{"date":346,"type":30},"2025-06-25",{"date":348,"type":30},"2022-12-15",{"date":350,"type":19},"2026-05-15",{"name":352,"class":37},"Tanta University",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":367,"leadSponsor":368,"locationsCount":4},"100596272","risk-factors-for-deep-sternal-wound-infection-after-coronary-artery-bypass-grafting-100596272","NCT07043296","Risk Factors for Deep Sternal Wound Infection After Coronary Artery Bypass Grafting","Inclusion Criteria:\n\n* All patients for CABG operation\n\nExclusion Criteria:\n\n* patients who died during operations or shortly after it.",{"count":360,"type":19},60,"Deep sternal wound infection (DSWI) constitutes a serious complication after coronary artery bypass grafting (CABG) surgery with potentially devastating consequences for patients. (1) Although median sternotomy is known to offer an excellent approach in CBAG, the impact of DSWI on patient prognosis remains significant. (2) The advances made in the field of prevention allowed the incidence of DSWI to decrease drastically in CBAG operations. (3,4) DSWI has been shown to lead to life- threatening complications linked with an increase in long and short-term mortality, morbidity, cost of care, prolonged hospital stays and in-hospital mortality. (5-8) There are a reported numerous risk factors potentially contributing to the development of DSWI in CABG, including the use of the internal thoracic artery for revascularization, long operative time, reoperation, an excessive use of bone wax and electrocoagulation, peripheral mechanical ventilation and other patient- related immunosuppressive risk factors. (9,10) Metabolic disorders such as diabetes, hypertension, dyslipidaemia and obesity leading to increased risk of poor clinical outcomes. (11) The aim of this study is determine the cut off point for some of known risk factors for deep sternal wound infection after Coronary artery bypass grafting.",[25],"2025-06-20",{"date":365,"type":30},"2025-06-29",{"date":321,"type":19},{"date":108,"type":19},{"name":369,"class":37},"Assiut University",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":79,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":38},"100526959","safety-and-efficacy-of-remote-ischemic-conditioning-for-patients-taking-off-pump-coronary-artery-bypass-grafting-100526959","NCT06141525","Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting","Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting (IMPROVE): A National, Multi-center, Randomized, Controlled, Open-label, Blinded-endpoint Trial","IMPROVE","Inclusion Criteria:\n\n* Diagnosed with coronary artery disease and require off-pump CABG surgery.\n* Between 18 and 75 years old;\n* Normal left ventricular systolic function (ejection fraction \\>40%) and left ventricular end-diastolic internal diameter (\\\u003C60 mm) in the cardiac ultrasound tests;\n* No or mild heart valve and great vessel abnormalities which do not require surgical intervention;\n* Participants or their authorized relatives agree to participate in the clinical trial and sign the informed consent.\n\nExclusion Criteria:\n\n* Severe tissue injuries.\n* Myalgia, fractures and other peripheral vascular lesions.\n* Bypass graft being the radial artery.\n* Stenosis or severe malformations of the subclavian, jugular and femoral arteries and veins.\n* Previous vagus nerve trunk dissection or vagus nerve block surgery.\n* Other surgical operations at the same time.\n* Patients with pre-existing severe cardiac insufficiency, acute coronary syndromes, malignant hypertension and cardiogenic shock.\n* Severe coagulation abnormality or severe anemia.\n* Severe mental disorder.\n* Malignant tumors.\n* Pregnant or lactating.\n* Increased risk of treatment for patients, according to investigators.\n* Refuse to sign the informed consent form.","70 Years",{"count":380,"type":19},648,[81],"Remote ischemic conditioning (RIC) is the process of repeated ischemia and reperfusion in the peripheral vessels, which is proved in reducing IRI in vital organs. This IMPROVE trial plans to enroll 648 patients who are diagnosed with coronary artery disease and are going to take off-pump CABG in five centers in China, to access whether RIC can and improve short-term prognosis.",[25,384,385],"Remote Ischemic Conditioning","Ischemia-Reperfusion Injury","2024-07-10",{"date":388,"type":30},"2024-07-12",{"date":390,"type":30},"2023-11-22",{"date":392,"type":19},"2029-03-31",{"name":394,"class":37},"First Affiliated Hospital Xi'an Jiaotong University",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":79,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":38},"100516206","the-effect-of-virtual-reality-on-postoperative-pain-and-anxiety-in-cardiac-surgery-100516206","NCT06001502","The Effect of Virtual Reality on Postoperative Pain and Anxiety in Cardiac Surgery.","VRECOVERY","Inclusion Criteria:\n\n* Age ≥18 years or older with written informed consent\n* Patients undergoing surgical CABG\n\nExclusion Criteria:\n\n* Major comorbidities besides coronary artery disease\n* Complicated surgical procedure\n* Hearing and\u002For visual impairments\n* Psychiatric impairments\n* Complaints of vomiting and nausea\n* History of epilepsy\n* Claustrophobia\n* Facial wounds and skin defects at site of application\n* Patients placed in clinical isolation\n* Readmission to the intensive care unit",{"count":403,"type":19},100,[81],"The objective of this study is to investigate the effect of VR on post-operative pain and anxiety management in cardiac surgery patients undergoing a coronary artery bypass grafting (CABG) procedure.\n\nParticipants in the intervention group will receive a 20 minute session with the head mounted VR device on post-operative days 1,2 and 3.\n\nParticipants in the control group will be treated with conventional post-operative care.",[407,408,409,25,410],"Post Operative Pain","Post Operative Anxiety","Heart Surgery","Virtual Reality","2024-07-09",{"date":386,"type":30},{"date":414,"type":30},"2023-01-01",{"date":416,"type":19},"2024-09-01",{"name":418,"class":37},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":15,"minAge":427,"maxAge":378,"enrollmentInfo":428,"targetDuration":4,"studyType":79,"phases":430,"briefSummary":431,"conditions":432,"keywords":434,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":38},"100507727","remimazolam-for-postoperative-atrial-fibrillation-100507727","NCT05891145","Remimazolam for Postoperative Atrial Fibrillation","The Effect of Remimazolam on Postoperative New-onset Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting","RePAF","Inclusion Criteria:\n\n* 50-70 years old;\n* BMI 18-28 kg\u002Fm2；\n* Selective CABG surgery will be performed at the Yangzhou Institute Heart and Great Vessels, the Affiliated Hospital of Yangzhou University, Yangzhou, China.\n* Patients agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* with any other type of cardiac surgery;\n* pre-operative supraventricular arrhythmia;\n* with moderate or severe valve disease before surgery;\n* with a history of chemotherapy or radiotherapy;\n* with a history of thoracic or cardiovascular surgery;\n* diuretics usage before the surgery.","50 Years",{"count":429,"type":19},50,[81],"Atrial fibrillation (AF) is the most common cardiac severe arrhythmia globally and is associated with an increased risk of mortality and morbidity, with a loss of 6.0 million disability-adjusted life-years worldwide in 2017, conferring 0.24% of total disability-adjusted life-years globally. Due to the absence of knowledge of AF pathogenesis, currently, available therapies do not prevent AF onset or progression in 85% of patients. Despite the identification of novel druggable targets that are involved in the pathogenesis of AF, the translation of these findings to clinical drug studies is limited.\n\nPostoperative atrial fibrillation (POAF) is the most common type of secondary AF. The incidence of POAF after coronary artery bypass grafting (CABG) is approximately 30%. About 16% of patients developed POAF in cardiac surgery even with the international guideline recommended perioperative beta-blocker intervention.\n\nRemimazolam is a newly approved benzodiazepine sedative indicated for the induction and maintenance of procedural sedation in adults, with significantly reduced sedation and recovery time. It was also found to be with an anti-inflammatory effect and therefore might have an impact on POAF since AF is closely related to the inflammatory response of myocardial tissue and inflammatory factors such as TNF-α. So, the RePAF trial intends to explore whether remimazolam application in induction and maintenance for general anesthesia during cardiac surgery can reduce the incidence of POAF in patients with CABG, and the effect on the postoperative plasma levels of inflammatory factors and stress factors.",[25,433],"Remimazolam",[433,95,435,436,437,438,439,440,441,442,443],"Postoperative atrial fibrillation","Postoperative new-onset atrial fibrillation","Coronary artery disease","CAD","Coronary artery bypass graft","Myocardial infarction","Revascularization","Anesthesia","Ischemic heart disease","2023-06-05",{"date":446,"type":30},"2023-06-06",{"date":448,"type":30},"2023-02-01",{"date":450,"type":19},"2026-12",{"name":452,"class":37},"Yangzhou University",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":460,"targetDuration":4,"studyType":79,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":4},"100503431","complete-revascularization-via-inferior-part-sternotomy-100503431","NCT05835167","Complete Revascularization Via Inferior Part-sternotomy","Minimally Invasive Coronary Artery Bypass Grafting Achieving Complete Revascularization of Multivessel Coronary Artery Disease Via Inferior Part-Sternotomy (The ACRIS-MICABG Trial)","Inclusion Criteria:\n\nPatients who undergo primary isolated open-chest CABG with multi-vessel coronary disease(left main artery disease with right coronary artery disease,or three-vessel disease)\n\nExclusion Criteria:\n\n1. Single vessel disease, double vessel disease, left main artery disease without right coronary artery disease.\n2. Concomitant cardiac surgeries(i.e. valve repair or replacement, Maze surgery, left ventricular repair due to ventricular aneurysm).\n3. Redo CABG.\n4. Emergent CABG.\n5. Left ventricular ejection fraction(EF≤35%).\n6. Severe atherosclerosis of the ascending aorta.\n7. Subjects tend to choose surgical approach (via full median sternotomy\u002Finferior part-sternotomy) .\n8. Malignant tumor or other severe systemic diseases.\n9. Severe renal insufficiency (i.e. creatinine \\>200 μmol\u002FL).\n10. Contraindications for dual antiplatelet therapy, such as active gastroduodenal ulcer.\n11. Participant of other ongoing clinical trials.",{"count":260,"type":19},[81],"To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy, We aim to randomize 260 patients undergoing isolated Coronary artery bypass grafting (CABG) to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China.",[464,25,465],"Complete Revascularization","Multivessel Coronary Artery Disease","2023-04-27",{"date":468,"type":30},"2023-04-28",{"date":470,"type":19},"2023-05-05",{"date":472,"type":19},"2035-05-04",{"name":474,"class":67},"China National Center for Cardiovascular Diseases",{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":15,"minAge":335,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":483,"conditions":484,"keywords":488,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":503,"locationsCount":38},"100301846","frailty-syndrome-in-daily-practice-of-interventional-cardiology-ward-100301846","NCT03209414","Frailty Syndrome in Daily Practice of Interventional Cardiology Ward","FRAPICA","Inclusion Criteria:\n\n* aged ≥ 65\n* symptomatic coronary artery disease A) stable B) unstable C) NSTEMI D) STEMI\n* written, informed consent\n\nExclusion Criteria:\n\n* lack of consent",{"count":47,"type":19},"The impact of frailty on immediate and long term outcomes of invasive treatment of coronary artery disease is not fully characterized. The assessment of frailty may help physicians in the selection of best treatment option and in the timing and modality of the follow-up. The FRAilty syndrome in daily Practice of Interventional CArdiology ward (FRAPICA) study is designed with the aim to validate the use of the Fried frailty scale and instrumental activities of daily living scale (IADL) as prognostic tools in patients admitted to hospital for symptomatic coronary artery disease, either stable, unstable, or acute coronary syndrome (ACS).\n\nThe FRAPICA study is a single center prospective study enrolling patients aged ≥65 years. The aims are (1) to describe Fried frailty scale and IADL scale distribution before hospital discharge and (2) to investigate the prognostic role of Fried frailty and IADL scores. The outcomes are: (1) results of invasive treatment, (2) its complications (periinterventional MI, contrast-induced nephropathy, blood loss), (3) three-year all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, reintervention, heart failure, hospital readmission for any cause, and a composite of the above mentioned. Ancillary analyses will be focused on different clinical presentations, different tools to assess frailty and risk stratification.\n\nThe FRAPICA program will fill critical gaps in the understanding of the relation between frailty, cardiovascular disease, interventional procedures and outcome. It will enable more personalized risk assessment and identification of new targets for interventions.",[485,316,486,25,487],"Frail Elderly Syndrome","Acute Coronary Syndrome","Percutaneous Transluminal Coronary Angioplasty",[489,490,491,492,493,494,495,496],"Frailty syndrome","Coronary heart disease","Coronary revascularization","Major adverse cardiovascular events","Arterial stiffness","Applanation tonometry","Lean body mass","ST2 biomarker","2023-04-10",{"date":499,"type":30},"2023-04-12",{"date":501,"type":30},"2017-05-17",{"date":195,"type":19},{"name":504,"class":37},"Medical University of Silesia"]